Counseling Points - March 2008 - (Page 14)

Counseling Points™ Pharmacological and Nonpharmacological Treatment of Rheumatoid Arthritis Continuing Education Posttest To receive credit, please read the newsletter in its entirety and answer the posttest and program evaluation questions using the answer key on page 15. Please mail or fax the form to Delaware Media Group, 66 South Maple Ave., Ridgewood, NJ 07450, Fax (201) 612-8282. (If you are completing the posttest online, simply hit the “submit” button.) A certificate from the Infusion Nurses Society will be awarded for a score of 80% (8 correct) or better. A certificate will be mailed within 4 to 6 weeks.There is no charge for CE credit. 1. Occupational therapy interventions for rheumatoid arthritis (RA) include: A) laser treatment and balneotherapy B) splinting, orthoses, and assistive devices C) assistive devices, exercise, and electrical stimulation D) athroplasty, acupuncture, meditation 2. The three primary classes of medications used to treat RA are: A) NSAIDs, corticosteroids, and DMARDs B) NSAIDs, beta-blockers, opiates C) opiates, anticoagulants, DMARDs D) antiplatelet medications, corticosteroids, proton pump inhibitors 3. NSAIDs work primarily by controlling pain and inflammation through targeting: A) lipoxygenase B) cyclooxygenase C) allergic response mechanisms D) none of the above 4. The types of corticosteroids that treat arthritis are: A) corticotropins B) anabolic-androgen steroids C) mineralocorticoids D) glucocorticoids 5. is considered first-line therapy for RA. A) Infliximab B) Methotrexate C) Sulfasalazine D) Anakinra 6. Leflunomide is safe and effective for women who are pregnant or planning a pregnancy. A) True B) False 7. The three TNF antagonists that are currently used to treat RA are: A) rituximab, methotrexate, adalimumab B) anakinra, rituximab, etanercept C) etanercept, infliximab, adalimumab D) infliximab, leflunomide, sulfasalazine 8. The recommended infusional fixed dose of abatacept is approximately: A) 1 mg/kg daily B) 3 mg/kg bi-monthly C) 10 mg/kg once per month after initial doses are given at baseline and 2 and 4 weeks D) none of the above 9. Following a single course of rituximab, beneficial effects of the drug may last as long as: A) 6 months to 2 years B) 4 weeks C) 3 years D) approximately 2 months 10. The most common adverse event of anakinra is injection site irritation and it occurs in approximately of patients. A) one-third B) half C) 10% D) two-thirds COUNSELING POINTS™ 14

Table of Contents Feed for the Digital Edition of Counseling Points - March 2008

Counseling Points - March 2008 Welcome Pharmacological and Nonpharmacological Treatment of Rheumatoid Arthritis

Counseling Points - March 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.